2016
London, UK, 02 August 2016 BTG plc (LSE: BTG), a global specialist healthcare company, today announced that it has obtained European Conformity (CE) Mark from the Notified Body British Standards...
London, UK, 27 July 2016 BTG plc (LSE: BTG), the specialist healthcare company, today announces the appointment of Graham Hetherington as a non-executive director of the Board and Chair of the...
London, UK, 14 July 2016 BTG plc (LSE: BTG), the specialist healthcare company provides the following business update ahead of its Annual General Meeting, which will be held today at 10.30 am at...
West Conshohocken, PA, US, 06 July 2016 BTG plc (LSE:BTG), the specialist healthcare company, announced that the U.S. Food and Drug Administration has approved an extension of the post-activation...
London, UK, 15 June 2016 BTG plc (LSE: BTG), the specialist healthcare company, is pleased to announce that it has completed the acquisition of Galil Medical, a leading provider of cryoablation...
London, UK, 09 June 2016 BTG, a global leader in interventional oncology, announced today that it has joined the Global Liver Institute’s Partnership Network as a founding member. The Global...
02 June 2016 BTG plc (LSE: BTG), a global specialist healthcare company, today announced plans to initiate the TheraSphere® Advanced Dosimetry Retrospective Global Study Evaluation in...
WASHINGTON D.C, 26 May 2016 New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma TARE (transarterial radio-embolization)...
London, UK, 17 May 2016 BTG plc (LSE: BTG), the specialist healthcare company, today announces its final results for the year ended 31 March 2016. Click here to download the results release PDF
London, UK, 06 May 2016 Builds on BTG’s leadership in Interventional Oncology, expanding franchise into attractive and complementary ablation market Galil Medical is a leader in cryoablation of...
London, UK, 05 April 2016 Selective internal radiation therapy (SIRT), including TheraSphere®, reimbursed by Zorginstituut Nederland BTG plc (LSE: BTG), a global specialist healthcare company is...
London, UK, 05 April 2016 BTG plc (LSE:BTG), the specialist healthcare company, provides the following update for the year ended 31 March 2016 ahead of the publication of its Final Results on 17...
London, UK, 02 April 2016 BTG to initiate multi-centre TARGET study evaluating dosimetry for 90Y radioembolisation therapy in patients with hepatocellular carcinoma BTG plc (LSE: BTG), a global...
London, UK, 01 April 2016 BTG announces US launch of LC Bead LUMI™, ground-breaking radiopaque embolic bead First and only, commercially available, radiopaque embolic bead in the US has...
London, UK, 10 March 2016 DC Bead®, DC BeadM1® and Bead Block® Now Sold Directly to Specialist Physicians Across Canada BTG International Canada Inc., part of the international specialty...
London, UK, 03 February 2016 BTG plc (LSE: BTG), a global specialist healthcare company, and Royal Philips (NYSE: PHG; AEX: PHIA), announced today a significant milestone in their collaboration...
London, UK, 26 January 2016 BTG plc (LSE: BTG), the specialist healthcare company, today announced the first treatment of patients in South Korea with TheraSphere® – a treatment for primary...
London, UK, 20 January 2016 BTG plc (LSE: BTG) announced today the presentation of new data for Vistogard® (uridine triacetate) oral granules at the American Society of Clinical Oncology...
London, UK, 09 March 2016 Results Demonstrate Reduced Disability for Patients Treated with CroFab® BTG plc (LSE: BTG) announced today the presentation of new data from the largest prospective...